SynCore Biotechnology Co (ROCO:4192) Ending Cash Position: NT$138.69 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4192 SynCore Biotechnology Co Ltd ROCO:4192
69 GF Score
Price NT$18.85
GF Value NT$40.62
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is SynCore Biotechnology Co Ending Cash Position?

SynCore Biotechnology Co ROCO:4192 -0.26% 69 Ending Cash Position is NT$138.69 Mil as of Jun. 2026. GuruFocus rates ROCO:4192 with a GF Score™ of 69/100 and a GF Value™ of NT$40.62 (Significantly Undervalued). The stock has 1 warning sign investors should review.

SynCore Biotechnology Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$138.69 Mil.

SynCore Biotechnology Co's quarterly Ending Cash Position declined from Dec. 2025 (NT$157.33 Mil) to Mar. 2026 (NT$149.12 Mil) and declined from Mar. 2026 (NT$149.12 Mil) to Jun. 2026 (NT$138.69 Mil).

SynCore Biotechnology Co's annual Ending Cash Position declined from Dec. 2023 (NT$264.70 Mil) to Dec. 2024 (NT$205.49 Mil) and declined from Dec. 2024 (NT$205.49 Mil) to Dec. 2025 (NT$157.33 Mil).

SynCore Biotechnology Co Ending Cash Position Related Terms

SynCore Biotechnology Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SynCore Biotechnology Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynCore Biotechnology Co Ending Cash Position Chart

SynCore Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 552.97 269.15 264.70 205.49 157.33

SynCore Biotechnology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.37 171.28 157.33 149.12 138.69
ROCO:4192
69GF Score
SynCore Biotechnology Co Ltd ROCO:4192
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynCore Biotechnology Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SynCore Biotechnology Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=205.487+-48.153
=157.33

SynCore Biotechnology Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=149.115+-10.426
=138.69

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$138.69 Mil mean?
SynCore Biotechnology Co (ROCO:4192) has a Ending Cash Position of NT$138.69 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SynCore Biotechnology Co and its competitors.
Is SynCore Biotechnology Co's Ending Cash Position too high?
SynCore Biotechnology Co's current Ending Cash Position is NT$138.69 Mil. Overall, SynCore Biotechnology Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SynCore Biotechnology Co's Ending Cash Position compare to VRTX and REGN?
SynCore Biotechnology Co's Ending Cash Position of NT$138.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SynCore Biotechnology Co and its competitors. SynCore Biotechnology Co's current Ending Cash Position is NT$138.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynCore Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, SynCore Biotechnology Co (ROCO:4192) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$40.62, compared to a current price of NT$18.85 — trading 53.6% below its estimated fair value. The current Ending Cash Position is NT$138.69 Mil. SynCore Biotechnology Co's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SynCore Biotechnology Co (ROCO:4192), the current Ending Cash Position is NT$138.69 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SynCore Biotechnology Co (ROCO:4192) Overvalued in 2026?

Based on GuruFocus' analysis, SynCore Biotechnology Co stock appears to be undervalued. The current stock price of NT$18.85 is trading 53.6% below its estimated GF Value™ of NT$40.62. GuruFocus considers SynCore Biotechnology Co to be Significantly Undervalued.

Key valuation signals for ROCO:4192:

  • Ending Cash Position: NT$138.69 Mil
  • GF Value™: NT$40.62 vs. price of NT$18.85 (53.6% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4192 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SynCore Biotechnology Co Business Description

Address No. 84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269
SynCore Biotechnology Co Ltd is a biotechnology company. The pipeline products of the company include SB01 and 02, SB03, SB04, SB05, and Others. It is engaged in new drug development and sales, healthy food development and sales, medicine inspection, biotechnology services, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from medical products and healthy food.
69GF Score

Get the complete analysis for ROCO:4192

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.85
Price
NT$40.62
GF Value